

(10-2003)

10 CFR 2.201

SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION

1. LICENSEE/LOCATION INSPECTED:

Progressive Medical Imaging and Minimally
Invasive Therapeutics, PLC
302 Center Avenue
Bay City, MI 48708

2. NRC/REGIONAL OFFICE

UNITED STATES
NUCLEAR REGULATORY COMMISSION
REGION III
2443 WARRENVILLE ROAD, SUITE 210
LISLE, IL 60532-4352

REPORT 2006-001

3. DOCKET NUMBER(S)

030-36919

4. LICENSEE NUMBER(S)

21-32568-01

5. DATE(S) OF INSPECTION

January 20, 2006

LICENSEE:

The inspection was an examination of the activities conducted under your license as they relate to radiation safety and to compliance with the Nuclear Regulatory Commission (NRC) rules and regulations and the conditions of your license. The inspection consisted of selective examinations of procedures and representative records, interviews with personnel, and observations by the inspector. The inspection findings are as follows:

- ☒ 1. Based on the inspection findings, no violations were identified.
- ☐ 2. Previous violation(s) closed.
- ☐ 3. The violation(s), specifically described to you by the inspector as non-cited violations, are not being cited because they were self-identified, non-repetitive, and corrective action was or is being taken, and the remaining criteria in the NRC Enforcement Policy, NUREG-1600, to exercise discretion, were satisfied.


Non-Cited Violation(s) was/were discussed involving the following requirement(s) and Corrective Action(s):

- ☐ 4. During this inspection certain of your activities, as described below and/or attached, were in violation of NRC requirements and are being cited. This form is a NOTICE OF VIOLATION, which may be subject to posting in accordance with 10 CFR 19.11.

(Violations and Corrective Actions)

Licensee's Statement of Corrective Actions for Item 4, above.

I hereby state that, within 30 days, the actions described by me to the inspector will be taken to correct the violations identified. This statement of corrective actions is made in accordance with the requirements of 10 CFR 2.201 (corrective steps already taken, corrective steps which will be taken, date when full compliance will be achieved). I understand that no further written response to NRC will be required, unless specifically requested.

Title	Printed Name	Signature	Date
LICENSEE'S REPRESENTATIVE			
NRC INSPECTOR	Robert P. Hays		1/20/2006

1-28

(10-2003)
10 CFR 2.201**Docket File Information
SAFETY INSPECTION REPORT
AND COMPLIANCE INSPECTION**

1. LICENSEE Progressive Medical Imaging & M.I.T., PLC		2. NRC/REGIONAL OFFICE Region III	
REPORT NUMBER(S) 2006-001			
3. DOCKET NUMBER(S) 03036919	4. LICENSEE NUMBER(S) 21-32568-01	5. DATE(S) OF INSPECTION January 20, 2006	
6. INSPECTION PROCEDURES USED 87131	7. INSPECTION FOCUS AREAS 03.01 - 03.07		
SUPPLEMENTAL INSPECTION INFORMATION			
1. PROGRAM CODE(S) 02120	2. PRIORITY 3	3. LICENSEE CONTACT Jeff Slowinski, CNMT	4. TELEPHONE NUMBER 989/797-3000
Next Inspection Date: January 2009			
<input checked="" type="checkbox"/> Main Office Inspection			
<input type="checkbox"/> Field 4200 Fashion Square Blvd., Saginaw, MI			
<input type="checkbox"/> Temporary Job Site			

PROGRAM SCOPE

The licensee was an out-patient medical facility located in Saginaw, Michigan, with authorization by the license to use any byproduct material permitted by 10 CFR 35.100, 35.200, and 35.300, not to exceed 1 curie. Licensed activities were initiated during September 2005 with one nuclear medicine technologist (NMT) routinely performing four diagnostic procedures/administrations per day for routine cardiac tests, bone scans, or other studies/scans as ordered. One I-131 dosage of 140 millicuries has been administered and other dosages less than 30 millicuries average one procedure per month. The licensee receives unit doses from a Saginaw, MI, nuclear pharmacy.

Performance Observations

During the inspection, licensee's NMTs demonstrated/discussed: (1) survey meter use and calibration; (2) package receiving and check-in procedures; (3) dose prep and safe use; (4) package wipe test counting; (5) dosimetry; (6) dose calibrator tests; (7) waste handling; (8) security of licensed material; (9) sealed source inventory; (10) radiation safety program audits; and (11) iodine-131 procedures and written procedures.